Copyright
©The Author(s) 2022.
World J Gastroenterol. Jul 28, 2022; 28(28): 3720-3731
Published online Jul 28, 2022. doi: 10.3748/wjg.v28.i28.3720
Published online Jul 28, 2022. doi: 10.3748/wjg.v28.i28.3720
Table 1 Top 10 countries published Clostridium difficile-associated diarrhea between 2001 and 2020
Position | Country | No. of publication | % |
1st | United States | 3585 | 44.11 |
2nd | United Kingdom | 1013 | 12.46 |
3rd | Canada | 556 | 6.84 |
4th | Germany | 434 | 5.34 |
5th | France | 383 | 4.71 |
6th | China | 315 | 3.88 |
7th | Netherlands | 273 | 3.36 |
8th | Australia | 261 | 3.21 |
9th | Italy | 244 | 3.00 |
10th | Spain | 238 | 2.93 |
Table 2 Ten most productive and influential institutions in Clostridium difficile-associated diarrhea between 2001 and 2020
Position | Institution | Country | No. of publication | % |
1st | University of Leeds | United Kingdom | 203 | 2.50 |
2nd | Leiden University Medical Center-LUMC | Netherlands | 191 | 2.35 |
3rd | Harvard Medical School | United States | 183 | 2.25 |
4th | VA Medical Center | United States | 173 | 2.13 |
5th | Leeds Teaching Hospitals NHS Trust | United Kingdom | 160 | 1.97 |
6th | Beth Israel Deaconess Medical Center | Israel | 135 | 1.66 |
7th | Washington University School of Medicine in St. Louis | United States | 118 | 1.45 |
8th | Edward Hines Jr. VA Hospital | United States | 115 | 1.42 |
9th | The University of Western Australia | Australia | 109 | 1.34 |
10th | Baylor College of Medicine | United States | 108 | 1.33 |
Table 3 Top 10 related funding agencies in Clostridium difficile-associated diarrhea between 2001 and 2020
Position | Funding agencies | Country | No. of publication | % |
1st | National Institutes of Health | United States | 884 | 10.88 |
2nd | U.S. Department of Health and Human Services | United States | 841 | 10.35 |
3rd | National Institute of Allergy and Infectious Diseases | United States | 539 | 6.63 |
4th | National Institute of Diabetes and Digestive and Kidney Diseases | United States | 239 | 2.94 |
5th | Merck | United States | 171 | 2.10 |
6th | National Center for Advancing Translational Sciences | United States | 154 | 1.89 |
7th | Medical Research Council | United Kingdom | 150 | 1.85 |
8th | National Institute of General Medical Sciences | United States | 146 | 1.80 |
9th | Pfizer | United States | 137 | 1.69 |
10th | United Kingdom Research and Innovation | United Kingdom | 132 | 1.62 |
Table 4 Ten most productive and influential journals in Clostridium difficile-associated diarrhea between 2001 and 2020
Position | Journal | n | % | IF1 |
1st | Infection Control and Hospital Epidemiology | 304 | 3.74 | 3.254 |
2nd | Anaerobe | 276 | 3.4 | 3.331 |
3rd | Clinical Infectious Diseases | 251 | 3.09 | 9.097 |
4th | Journal of Hospital Infection | 212 | 2.61 | 3.926 |
5th | Journal of Clinical Microbiology | 183 | 2.25 | 5.948 |
6th | Plos One | 181 | 2.23 | 3.240 |
7th | American Journal of Infection Control | 169 | 2.08 | 2.918 |
8th | Antimicrobial Agents and Chemotherapy | 130 | 1.6 | 5.191 |
9th | Journal of Antimicrobial Chemotherapy | 124 | 1.53 | 5.790 |
10th | Clinical Microbiology and Infection | 117 | 1.44 | 8.067 |
Table 5 Ten most cited publications and authors between 2001 and 2020 in in Clostridium difficile-associated diarrhea
Ref. | Title | Year | Source title | Cited by | Citation index | Impact index per article1 |
Cohen et al[35] | “Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)” | 2010 | Infection Control and Hospital Epidemiology | 2370 | 237.0 | 313.9 |
van Nood et al[42] | “Duodenal infusion of donor feces for recurrent clostridium difficile” | 2013 | New England Journal of Medicine | 2140 | 305.7 | 241.3 |
Loo et al[37] | “A predominantly clonal multi-institutional outbreak of Clostridium difficile - Associated diarrhea with high morbidity and mortality” | 2005 | New England Journal of Medicine | 1601 | 106.7 | 88.6 |
Lessa et al[44] | “Burden of Clostridium difficile infection in the United States” | 2015 | New England Journal of Medicine | 1430 | 286.0 | 234.3 |
Surawicz et al[41] | “Guidelines for diagnosis, treatment, and prevention of clostridium difficile infections” | 2013 | American Journal of Gastroenterology | 1087 | 155.3 | 116.8 |
Louie et al[38] | “Fidaxomicin versus vancomycin for Clostridium difficile infection” | 2011 | New England Journal of Medicine | 1074 | 119.3 | 91.4 |
Kelly and LaMont[36] | “Clostridium difficile - More difficult than ever” | 2008 | New England Journal of Medicine | 1019 | 84.9 | 68.1 |
Rupnik et al[40] | “Clostridium difficile infection: New developments in epidemiology and pathogenesis” | 2009 | Nature Reviews Microbiology | 985 | 89.5 | 73.4 |
Zar et al[43] | “A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity” | 2007 | Clinical Infectious Diseases | 935 | 71.9 | 58.9 |
Pépin et al[39] | “Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: A changing pattern of disease severity” | 2004 | CMAJ | 916 | 57.3 | 45.6 |
- Citation: Zyoud SH. Global research on Clostridium difficile-associated diarrhoea: A visualized study. World J Gastroenterol 2022; 28(28): 3720-3731
- URL: https://www.wjgnet.com/1007-9327/full/v28/i28/3720.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i28.3720